Semi-Synthetic Membrane Nanoparticles for Precision Payload Delivery

This innovative semi-synthetic platform combines the targeting intelligence of natural cell proteins with the structural perfection and scalability of synthetic lipids. By delivering a highly reproducible, fully wrapped nanoparticle that resists immune clearance, it provides biopharmaceutical developers with a high-yield, regulatory-friendly vehicle to optimize the localized delivery of diverse therapeutic payloads.

Background

The field of targeted nanomedicine focuses on developing biomimetic carriers capable of transporting delicate therapeutics directly to specific disease sites while evading the body’s immune defenses. To achieve this, researchers have relied on coating nanoparticle cores with natural cell-derived membranes; however, this approach presents significant barriers to clinical translation. Natural membranes are compositionally complex, leading to severe batch-to-batch variability and a complex extraction process that limits manufacturing yield. Most critically, natural membranes frequently fail to completely wrap the nanoparticle cores, leaving the underlying surface exposed to serum protein opsonization, which triggers premature drug release and rapid clearance by the immune system before the cargo can reach challenging targets like triple-negative breast cancer. 

Technology

University of Delaware Researchers have developed an advanced drug delivery platform. This technology addresses these scaling and coating limitations by using a semi-synthetic membrane architecture to form a uniform 150 nm core-shell structure over polymeric nanoparticles. The technology extracts functional membrane proteins from cultured cells and reconstitutes them into fully customized, synthetic lipid bilayers, maintaining an exceptional 84% protein retention rate while ensuring chemical homogeneity. Unlike traditional methods that suffer from incomplete wrapping, the synthetic lipid components ensure complete, continuous surface coverage that entirely prevents opsonization and accidental cargo leakage. Because the native biological functions of the homing proteins are preserved within a predictable, programmable lipid shell, this modular platform effectively evades immune detection and modulates biodistribution for the targeted delivery of small molecules, biologics, and RNA therapeutics. This innovative semi-synthetic platform combines the targeting intelligence of natural cell proteins with the structural perfection and scalability of synthetic lipids.

Benefits

  • Complete Core Wrapping: Ensures continuous, leak-proof surface coverage of the nanoparticle core, preventing premature cargo release and protecting it from immune-system opsonization.

  • Scalable & Regulatory-Friendly: Replaces highly variable natural cell extractions with a programmable, chemically homogeneous manufacturing process that offers significant quality control advantages.

  • Preserved Biological Homing: Retains the native target-seeking functions of membrane proteins, enabling precise accumulation at disease sites. 

  • Highly Versatile & Modular: Features a flexible architecture that allows precise control over lipid-to-protein ratios and accommodates a wide variety of cargo, including small molecules, large biologics, and RNA.

 

Applications

  • Targeted Cancer Therapeutics: Delivery of chemotherapy, RNA therapies, and biologics directly to solid tumors while minimizing off-target toxicity.

  • Oncology Biologics & Gene Therapy: Safe, targeted systemic delivery of fragile RNA, mRNA, and gene-editing therapeutics without premature degradation or immune clearance.

  • Autoimmune & Inflammatory Disease Treatments: Transporting immunosuppressive or anti-inflammatory drugs to specific diseased tissues while reducing systemic side effects.

  • Nanomedicine Contract Manufacturing (CDMO): Scalable, high-yield manufacturing platform for pharmaceutical companies producing standardized, cell-membrane-camouflaged nanoparticles.

  • Precision Drug Delivery Licensing: Versatile, modular carrier platform for drug developers seeking to improve the biodistribution and therapeutic index of candidate molecules.

Additional info

Semi-synthetic membrane platforms comprise isolated cell-membrane proteins reconstituted into customized synthetic lipid bilayers, encapsulating polymeric nanoparticle cores via thin-film hydration. This core-shell architecture features a continuous outer layer with a hydrodynamic diameter of approximately 150 nm and a -30 mV zeta potential. Retaining 84% of native membrane proteins, the platform prevents opsonization and premature cargo release while mediating targeted delivery and immune evasion for therapeutic and diagnostic payloads.